nach oben

Current Dermatology Reports

Erschienen in:

11.05.2017 | Psoriasis (J Wu, Section Editor)

Autoimmunity in Psoriasis: Evidence for Specific Autoantigens

verfasst von: Jason E. Hawkes, Jose A. Gonzalez, James G. Krueger

Erschienen in: Current Dermatology Reports | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The pathophysiology of psoriasis is highly complex, and the role of autoantigens in psoriasis has been debated for decades. In this article, we examine the evidence in support of psoriasis autoantigens and their contribution to the development of this chronic, inflammatory condition. We also provide an overview of the known biological functions of these psoriasis autoantigens and their potential role in the pathogenesis of psoriatic disease.

Recent Findings

Since 2014, three potential psoriasis autoantigens (LL-37, ADAMTSL5, and PLA2G4D) have been described in the scientific literature.

Summary

Current evidence lends support for the role of autoantigens in psoriasis and offers insights into the underlying mechanisms enabling the breakdown of immune tolerance in the skin. A systematic approach to identify novel psoriasis autoantigens is needed and has the potential to lead to the development of novel interventions and/or treatment strategies, including a possible cure for this condition.

Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–6. doi:10.1016/j.jaad.2013.11.013.CrossRefPubMed

Cohen AD, Dreiher J, Shapiro Y, Vidavsky L, Vardy DA, Davidovici B, et al. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol. 2008;22(5):585–9. doi:10.1111/j.1468-3083.2008.02636.x.CrossRefPubMed

Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology. 2008;216(2):152–5. doi:10.1159/000111512.CrossRefPubMed

Dreiher J, Weitzman D, Shapiro J, Davidovici B, Cohen AD. Psoriasis and chronic obstructive pulmonary disease: a case-control study. Br J Dermatol. 2008;159(4):956–60. doi:10.1111/j.1365-2133.2008.08749.x.CrossRefPubMed

Gelfand JM, Dommasch ED, Shin DB, Azfar RS, Kurd SK, Wang X, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol. 2009;129(10):2411–8. doi:10.1038/jid.2009.112.CrossRefPubMedPubMedCentral

Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–41. doi:10.1001/jama.296.14.1735.CrossRefPubMed

Shalom G, Dreiher J, Cohen A. Psoriasis and obstructive sleep apnea. Int J Dermatol. 2016; doi:10.1111/ijd.13367.PubMed

Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F, et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol. 2008;59(5):772–80. doi:10.1016/j.jaad.2008.06.043.CrossRefPubMed

Vanderpuye-Orgle J, Zhao Y, Lu J, Shrestha A, Sexton A, Seabury S, et al. Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol. 2015;72(6):961–7.e5. doi:10.1016/j.jaad.2015.02.1099.CrossRefPubMed

10.

Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509. doi:10.1056/NEJMra0804595.CrossRefPubMed

11.

Ellis CN, Gorsulowsky DC, Hamilton TA, Billings JK, Brown MD, Headington JT, et al. Cyclosporine improves psoriasis in a double-blind study. JAMA. 1986;256(22):3110–6.CrossRefPubMed

12.

Griffiths CE, Powles AV, Leonard JN, Fry L, Baker BS, Valdimarsson H. Clearance of psoriasis with low dose cyclosporin. Br Med J (Clin Res Ed). 1986;293(6549):731–2.CrossRef

13.

Ryan TJ, Baker H. Systemic corticosteroids and folic acid antagonists in the treatment of generalized pustular psoriasis. Evaluation and prognosis based on the study of 104 cases. Br J Dermatol. 1969;81(2):134–45.CrossRefPubMed

14.

Bos JD, Hagenaars C, Das PK, Krieg SR, Voorn WJ, Kapsenberg ML. Predominance of “memory” T cells (CD4+, CDw29+) over “naive” T cells (CD4+, CD45R+) in both normal and diseased human skin. Arch Dermatol Res. 1989;281(1):24–30.CrossRefPubMed

15.

Bos JD, Hulsebosch HJ, Krieg SR, Bakker PM, Cormane RH. Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res. 1983;275(3):181–9.CrossRefPubMed

16.

Eedy DJ, Burrows D, Bridges JM, Jones FG. Clearance of severe psoriasis after allogenic bone marrow transplantation. BMJ. 1990;300(6729):908.CrossRefPubMedPubMedCentral

17.

Krueger GG, Chambers DA, Shelby J. Involved and uninvolved skin from psoriatic subjects: are they equally diseased? Assessment by skin transplanted to congenitally athymic (nude) mice. J Clin Invest. 1981;68(6):1548–57.CrossRefPubMedPubMedCentral

18.

Chang JC, Smith LR, Froning KJ, Schwabe BJ, Laxer JA, Caralli LL, et al. CD8+ T cells in psoriatic lesions preferentially use T-cell receptor V beta 3 and/or V beta 13.1 genes. Proc Natl Acad Sci U S A. 1994;91(20):9282–6.CrossRefPubMedPubMedCentral

19.

Baker BS, Griffiths CE, Lambert S, Powles AV, Leonard JN, Valdimarsson H, et al. The effects of cyclosporine A on T lymphocyte and dendritic cell subpopulations in psoriasis. Transplant Proc. 1988;20(3 Suppl 4):72–7.PubMed

20.

Mozzanica N, Cattaneo A, Pigatto PD, Finzi AF. Cyclosporine A in psoriasis: an immunohistological study. Transplant Proc. 1988;20(3 Suppl 4):78–84.PubMed

21.

Gottlieb AB, Grossman RM, Khandke L, Carter DM, Sehgal PB, Fu SM, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992;98(3):302–9.CrossRefPubMed

22.

• Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995;1(5):442–7. Seminal paper with definitive proof for the role of pathogenic T cells in psoriasis. CrossRefPubMed

23.

Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest. 1999;103(9):1243–52. doi:10.1172/JCI5857.CrossRefPubMedPubMedCentral

24.

Krueger GG, Callis KP. Development and use of alefacept to treat psoriasis. J Am Acad Dermatol. 2003;49(2 Suppl):S87–97. doi:10.1016/mjd.2003.552.CrossRefPubMed

25.

Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349(21):2004–13. doi:10.1056/NEJMoa030002.CrossRefPubMed

26.

Menssen A, Trommler P, Vollmer S, Schendel D, Albert E, Gurtler L, et al. Evidence for an antigen-specific cellular immune response in skin lesions of patients with psoriasis vulgaris. J Immunol. 1995;155(8):4078–83.PubMed

27.

Harden JL, Hamm D, Gulati N, Lowes MA, Krueger JG. Deep sequencing of the T-cell receptor repertoire demonstrates polyclonal T-cell infiltrates in psoriasis. F1000Res. 2015;4:460. doi:10.12688/f1000research.6756.1.PubMedPubMedCentral

28.

Kirsch IR, Watanabe R, O’Malley JT, Williamson DW, Scott LL, Elco CP, et al. TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. Sci Transl Med. 2015;7(308):308ra158. doi:10.1126/scitranslmed.aaa9122.CrossRefPubMedPubMedCentral

29.

Johnston A, Gudjonsson JE, Sigmundsdottir H, Love TJ, Valdimarsson H. Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8(+) T cells. Clin Exp Immunol. 2004;138(1):83–93. doi:10.1111/j.1365-2249.2004.00600.x.CrossRefPubMedPubMedCentral

30.

Shen Z, Wang G, Fan JY, Li W, Liu YF. HLA DR B1*04, *07-restricted epitopes on keratin 17 for autoreactive T cells in psoriasis. J Dermatol Sci. 2005;38(1):25–39. doi:10.1016/j.jdermsci.2005.01.001.CrossRefPubMed

31.

Jin L, Wang G. Keratin 17: a critical player in the pathogenesis of psoriasis. Med Res Rev. 2014;34(2):438–54. doi:10.1002/med.21291.CrossRefPubMed

32.

Zanetti M. The role of cathelicidins in the innate host defenses of mammals. Curr Issues Mol Biol. 2005;7(2):179–96.PubMed

33.

Nagaoka I, Tamura H, Hirata M. An antimicrobial cathelicidin peptide, human CAP18/LL-37, suppresses neutrophil apoptosis via the activation of formyl-peptide receptor-like 1 and P2X7. J Immunol. 2006;176(5):3044–52.CrossRefPubMed

34.

Zasloff M. Antimicrobial peptides of multicellular organisms. Nature. 2002;415(6870):389–95. doi:10.1038/415389a.CrossRefPubMed

35.

• Lande R, Botti E, Jandus C, Dojcinovic D, Fanelli G, Conrad C, et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun. 2014;5:5621. doi:10.1038/ncomms6621. This study first demonstrated the presence of LL-37 specific T cells, which were found in 46% of patients with psoriasis. CrossRefPubMed

36.

• Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449(7162):564–9. doi:10.1038/nature06116. This paper showed that LL-37 complexes with self-DNA leading to TLR activation and subsequent pDC activation. CrossRefPubMed

37.

Zaiou M, Nizet V, Gallo RL. Antimicrobial and protease inhibitory functions of the human cathelicidin (hCAP18/LL-37) prosequence. J Invest Dermatol. 2003;120(5):810–6. doi:10.1046/j.1523-1747.2003.12132.x.CrossRefPubMed

38.

Kreuter A, Jaouhar M, Skrygan M, Tigges C, Stucker M, Altmeyer P, et al. Expression of antimicrobial peptides in different subtypes of cutaneous lupus erythematosus. J Am Acad Dermatol. 2011;65(1):125–33. doi:10.1016/j.jaad.2010.12.012.CrossRefPubMed

39.

Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, et al. Nucleic acids of mammalian origin can act as endogenous ligands for toll-like receptors and may promote systemic lupus erythematosus. J Exp Med. 2005;202(8):1131–9. doi:10.1084/jem.20050914.CrossRefPubMedPubMedCentral

40.

Paulsen F, Pufe T, Conradi L, Varoga D, Tsokos M, Papendieck J, et al. Antimicrobial peptides are expressed and produced in healthy and inflamed human synovial membranes. J Pathol. 2002;198(3):369–77. doi:10.1002/path.1224.CrossRefPubMed

41.

Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002;347(15):1151–60. doi:10.1056/NEJMoa021481.CrossRefPubMed

42.

Yamasaki K, Di Nardo A, Bardan A, Murakami M, Ohtake T, Coda A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13(8):975–80. doi:10.1038/nm1616.CrossRefPubMed

43.

Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med. 2001;194(6):863–9.CrossRefPubMedPubMedCentral

44.

Ronnblom L. The importance of the type I interferon system in autoimmunity. Clin Exp Rheumatol. 2016;34(4 Suppl 98):21–4.PubMed

45.

• Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med. 2005;202(1):135–43. doi:10.1084/jem.20050500. This study first demonstrated that pDCs are capable of initiating early psoriasis plaques. CrossRefPubMedPubMedCentral

46.

van der Does AM, Beekhuizen H, Ravensbergen B, Vos T, Ottenhoff TH, van Dissel JT, et al. LL-37 directs macrophage differentiation toward macrophages with a proinflammatory signature. J Immunol. 2010;185(3):1442–9. doi:10.4049/jimmunol.1000376.CrossRefPubMed

47.

• Tang X, Basavarajappa D, Haeggstrom JZ, Wan M. P2X7 receptor regulates internalization of antimicrobial peptide LL-37 by human macrophages that promotes intracellular pathogen clearance. J Immunol. 2015;195(3):1191–201. doi:10.4049/jimmunol.1402845. First paper showing the involvement of LL-37 in macrophages. CrossRefPubMedPubMedCentral

48.

Kawasaki T, Kawai T, Akira S. Recognition of nucleic acids by pattern-recognition receptors and its relevance in autoimmunity. Immunol Rev. 2011;243(1):61–73. doi:10.1111/j.1600-065X.2011.01048.x.CrossRefPubMed

49.

Barton GM, Kagan JC, Medzhitov R. Intracellular localization of toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat Immunol. 2006;7(1):49–56. doi:10.1038/ni1280.CrossRefPubMed

50.

• Chamilos G, Gregorio J, Meller S, Lande R, Kontoyiannis DP, Modlin RL, et al. Cytosolic sensing of extracellular self-DNA transported into monocytes by the antimicrobial peptide LL37. Blood. 2012;120(18):3699–707. doi:10.1182/blood-2012-01-401364. This study showed that LL-37 could cause an increase in type I IFNs via a TLR-independent manner. CrossRefPubMedPubMedCentral

51.

Ganguly D, Chamilos G, Lande R, Gregorio J, Meller S, Facchinetti V, et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med. 2009;206(9):1983–94. doi:10.1084/jem.20090480.CrossRefPubMedPubMedCentral

52.

Mabuchi T, Hirayama N. Binding affinity and interaction of LL-37 with HLA-C*06:02 in psoriasis. J Invest Dermatol. 2016;136(9):1901–3. doi:10.1016/j.jid.2016.04.033.CrossRefPubMed

53.

Apte SS. A disintegrin-like and metalloprotease (reprolysin-type) with thrombospondin type 1 motif (ADAMTS) superfamily: functions and mechanisms. J Biol Chem. 2009;284(46):31493–7. doi:10.1074/jbc.R109.052340.CrossRefPubMedPubMedCentral

54.

Bader HL, Wang LW, Ho JC, Tran T, Holden P, Fitzgerald J, et al. A disintegrin-like and metalloprotease domain containing thrombospondin type 1 motif-like 5 (ADAMTSL5) is a novel fibrillin-1-, fibrillin-2-, and heparin-binding member of the ADAMTS superfamily containing a netrin-like module. Matrix Biol. 2012;31(7–8):398–411. doi:10.1016/j.matbio.2012.09.003.CrossRefPubMedPubMedCentral

55.

• Arakawa A, Siewert K, Stohr J, Besgen P, Kim SM, Ruhl G, et al. Melanocyte antigen triggers autoimmunity in human psoriasis. J Exp Med. 2015;212(13):2203–12. doi:10.1084/jem.20151093. First paper implicating ADAMTSL5 as a peptide autoantigen in psoriasis. CrossRefPubMedPubMedCentral

56.

Conrad C, Boyman O, Tonel G, Tun-Kyi A, Laggner U, de Fougerolles A, et al. Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat Med. 2007;13(7):836–42. doi:10.1038/nm1605.CrossRefPubMed

57.

Abdel-Naser MB, Liakou AI, Elewa R, Hippe S, Knolle J, Zouboulis CC. Increased activity and number of epidermal melanocytes in lesional psoriatic skin. Dermatology. 2016;232(4):425–30. doi:10.1159/000447535.CrossRefPubMed

58.

Bonifacio KM, Kunjravia N, Krueger JG, Fuentes-Duculan J. Cutaneous expression of a disintegrin-like and metalloprotease domain containing thrombospondin type 1 motif-like 5 (ADAMTSL5) in psoriasis goes beyond melanocytes. J Pigment Disord. 2016;3(3). doi:10.4172/2376-0427.1000244.

59.

Chiba H, Michibata H, Wakimoto K, Seishima M, Kawasaki S, Okubo K, et al. Cloning of a gene for a novel epithelium-specific cytosolic phospholipase A2, cPLA2delta, induced in psoriatic skin. J Biol Chem. 2004;279(13):12890–7. doi:10.1074/jbc.M305801200.CrossRefPubMed

60.

Nevalainen TJ. Serum phospholipases A2 in inflammatory diseases. Clin Chem. 1993;39(12):2453–9.PubMed

61.

Bourgeois EA, Subramaniam S, Cheng TY, De Jong A, Layre E, Ly D, et al. Bee venom processes human skin lipids for presentation by CD1a. J Exp Med. 2015;212(2):149–63. doi:10.1084/jem.20141505.CrossRefPubMedPubMedCentral

62.

Subramaniam S, Aslam A, Misbah SA, Salio M, Cerundolo V, Moody DB, et al. Elevated and cross-responsive CD1a-reactive T cells in bee and wasp venom allergic individuals. Eur J Immunol. 2016;46(1):242–52. doi:10.1002/eji.201545869.CrossRefPubMed

63.

Grass DS, Felkner RH, Chiang MY, Wallace RE, Nevalainen TJ, Bennett CF, et al. Expression of human group II PLA2 in transgenic mice results in epidermal hyperplasia in the absence of inflammatory infiltrate. J Clin Invest. 1996;97(10):2233–41. doi:10.1172/JCI118664.CrossRefPubMedPubMedCentral

64.

Quaranta M, Knapp B, Garzorz N, Mattii M, Pullabhatla V, Pennino D, et al. Intraindividual genome expression analysis reveals a specific molecular signature of psoriasis and eczema. Sci Transl Med. 2014;6(244):244ra90. doi:10.1126/scitranslmed.3008946.CrossRefPubMed

65.

• Cheung KL, Jarrett R, Subramaniam S, Salimi M, Gutowska-Owsiak D, Chen YL, et al. Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a. J Exp Med. 2016;213(11):2399–412. doi:10.1084/jem.20160258. This paper was the first to demonstrate that PLA2G4D generates non-peptide neolipid autoantigens in psoriasis. CrossRefPubMedPubMedCentral

Titel: Autoimmunity in Psoriasis: Evidence for Specific Autoantigens
verfasst von: Jason E. Hawkes
Jose A. Gonzalez
James G. Krueger
Publikationsdatum: 11.05.2017
Verlag: Springer US
Erschienen in: Current Dermatology Reports / Ausgabe 2/2017
Elektronische ISSN: 2162-4933
DOI: https://doi.org/10.1007/s13671-017-0177-6

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

08.05.2024 Akne Nachrichten

Die Aknetherapie mit Isotretinoin kann einen Anstieg von Leberenzymen und Blutfetten verursachen. Das Risiko für schwere Störungen ist laut einer Forschungsgruppe der Universität Lübeck aber nur marginal erhöht und auf einen engen Zeitraum konzentriert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

The Role of the Skin and Gut Microbiome in Psoriatic Disease

Cutaneous Manifestations of Connective Tissue Disease in the Inpatient Setting

Systemic Therapy of Atopic Dermatitis: When, How, for How Long?

Update on Comorbidities in Psoriasis

Topical Therapy of AD: How to Reach Better Results